Atalanta Therapeutics
Atalanta Therapeutics pioneers treatments for CNS diseases using groundbreaking RNA interference technology, focusing on neurodegenerative conditions like Huntington’s, Parkinson’s, and Alzheimer’s diseases.
Company Overview
Atalanta Therapeutics, headquartered in Boston, MA, is a pioneering entity in the treatment of central nervous system (CNS) diseases. Founded in 2018 by experts from the RNA Therapeutics Institute at the University of Massachusetts Medical School, the company aims to address the urgent global need for interventions to treat neurodegenerative diseases.
Founders
Atalanta Therapeutics was founded by experts from the RNA Therapeutics Institute at the University of Massachusetts Medical School. The founders leveraged their extensive expertise in RNA science to create the company in 2018 with the goal of developing RNA interference-based therapies for CNS diseases.
Technology and Approach
Atalanta Therapeutics utilizes groundbreaking discoveries in RNA interference—a Nobel prize-winning discovery that allows for targeted silencing of disease-causing genes. The company's proprietary branched siRNA construct provides effective and prolonged gene silencing throughout the brain and spinal cord. This technology enables a single dose to perform gene silencing for six months or more in preclinical studies.
Therapeutic Areas
The initial therapeutic focus areas of Atalanta Therapeutics include Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. These neurodegenerative diseases are associated with heritable genes, many of which have been identified for targeted intervention using the company's RNAi technology.
Strategic Collaborations
Atalanta Therapeutics has established strategic collaborations with prominent pharmaceutical companies Biogen and Genentech. These partnerships aim to advance the development and potential commercialization of RNAi-based therapies for CNS diseases.